Indicative Announcement on Inclusion of Rekonkitta Monoclonal Antibody Injection into the Priority Review and Approval Program

About this update from Joincare Pharmaceutical Group Industry Co., Ltd. Class A

Indicative Announcement on Inclusion of Rekonkitta Monoclonal Antibody Injection into the Priority Review and Approval Program The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Joincare Pharmaceutical Group Industry Co., Ltd. Class A